Our first path to market is in skin cancer detection.
Twenty percent of Americans will receive a skin cancer diagnosis before the age of 70; many more will go through a biopsy procedure for suspected skin cancer.
The roughly 80% of skin biopsies in the United States do not result in a cancer diagnosis, adding unnecessary cost to the healthcare system.
The IRMedtek fast cancer detection probe increases early accuracy detection, improves efficiency, and reduces the unnecessary number of biopsies. It provides immediate information at a primary care visit.
The platform offers other paths to market with devices very similar to the initial product. These include cervical, oral, and anal cancers along with intraoperative and endoscopic procedures.